
Increasing Longevity by Unlocking Medicines Targeting Abnormal
LIpid MEtabolism
At Lime, we are inventing breakthrough lipid-targeting therapeutics using our novel drug discovery platform.
Lime Therapeutics is a fast-growing biotechnology company focused on making a difference for patients. We are a spinout company developing new technology invented at Memorial Sloan Kettering Cancer Center, and are using our breakthrough LipidSense™ platform to hunt for novel targets and create new drugs that modulate aberrant lipid metabolism in many forms of cancer, metabolic diseases, and neurodegenerative disorders.
Leadership
Scientific Advisory Board


Robert Schwartz, MD, PhD
Weill Cornell Medicine
Matthew
Vander Heiden, MD, PhD
Massachusetts Institute of Technology (MIT)

Rushika Perera, PhD
University of California,
San Francisco


Xuejun Jiang, PhD
Tuomas Tammela, MD, PhD
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Business Advisors


Jeff Hatfield, MBA
Robin Mansukhani
CEO, Deciduous Therapeutics
Chairman of the Board of Directors, Vividion Therapeutics, and Harvard Blavatnik Fellow Advisor

Parul Chachra, PhD, MBA
X (Google)
Technology
Creating Lipid-Altering Therapeutics

Cancers feed off nutrients, such as lipids (fats). In addition, excess lipid buildup is a hallmark of neurodegenerative disorders. Despite this, efforts to target lipid metabolism in cancer and neurodegenerative disorders have remained elusive due to lack of technology.
We've changed the game with the invention of an ultrasensitive lipid detection technology. LipidSense is a high-throughput screening platform that monitors lysosomal lipid flux in real time in live cells, in a well-plate format, and in live animals.
We can tell within seconds whether a particular therapy changes lipid flux. We are utilizing this platform to discover drugs that can alter cancer's access to lipids or restore lysosomal lipid function in neurodegenerative disorders.
The primary indication for our lead drug candidate is non-small cell lung cancer. We are also exploring therapeutic opportunities for this and other drugs in our pipeline for pancreatic, colorectal, and kidney cancer. Collectively, these four cancers represent a $50B total addressable market (TAM) and 462,000 patients diagnosed annually in the US.
Publications
A Carbon Nanotube Optical Reporter Maps Endolysosomal Lipid Flux.
Prakrit V. Jena, Daniel Roxbury, et. al.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707631/
An optical nanoreporter of endolysosomal lipid accumulation reveals enduring effects of diet on hepatic macrophages in vivo.
Thomas V. Galassi, Prakrit V. Jena, et. al.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543545/
Long-term in vivo biocompatibility of single-walled carbon nanotubes
Thomas V. Galassi, et. al., and Daniel Heller
News and Events
February 28, 2023
Bristol Myers Squibb Awards Lime Therapeutics with a “Golden Ticket”
February 28, 2023
CWRU’s Alumni Venture Fund Brings Together Medical Student and
Lime Therapeutics, a Life Sciences Startup
February 3, 2023
CWRU Alumni Venture Fund Combines Capital with Education Featuring Lime CEO, Dr. Shardule Shah
January 10, 2023
Lime Therapeutics Wraps Up Successful JPMorgan Healthcare Week
December 15, 2022
2022 Most Disruptive MBA Startups: Lime Therapeutics, Harvard Business School
Our Supporters
Thank you to those supporting our efforts to develop life-changing therapeutics (partial list):
_edited.png)
_edited.png)


Case Western Reserve University
Alumni Venture Fund
Kent Johnson, MBA
Former CFO, BioLegend

Little Green Bamboo
Invest together. Grow together.



Dr. Parag and Dulari Doshi
Chicago Cardiology Institute
Inaki Berenguer, PhD, MBA
Life Extension Ventures
Dr. Mahendra and Nalini Maru
If interested in pursuing an investment opportunity, please reach out.